T Cell Immunotherapy Articles & Analysis: Older
11 articles found
This heightened expression of CD19 makes it a valuable target for treating these diseases. CAR-T cell therapy, an immunotherapy, has demonstrated efficacy in treating B-cell lymphoma by genetically modifying the patient's T cells to carry CD19-specific receptors. ...
CAR T Cell Therapy CAR T cell therapy is another immunotherapy utilizing cytotoxic T cells. ...
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. ...
Researchers at Massachusetts General Hospital (MGH) have found that interferon gamma receptor (IFNgR) signaling is essential for the susceptibility of CAR-T cell immunotherapy to kill malignant gliomas. The same phenomenon has been observed in other solid tumors. ...
Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. ...
Targeting T cells in T1D CD4+ and CD8+ T cells orchestrate the inflammatory process that ultimately destroys islet β cells and leads to the development of T1D. ...
Immunotherapy, in addition to surgery, chemotherapy, and radiotherapy, has now become the fourth pillar of anticancer treatment, with T cell-based immunotherapy being a successful cancer treatment technique. ...
Using the power of large data and advanced computational methods, researchers can identify peptides on the surface of tumor cells and can target "peptide-centric" chimeric antigen receptors (PC-CARs): a new design of T cells that stimulates the immune response to eliminate tumors. ...
Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial toxicitythat is of particular concern in the elderly CLL population.Vg9Vd2-T cells form a conserved T-cell subset with strongintrinsic immunotherapeutic ...
Ryan Pawell is the founder and CEO of Indee Labs, a Berkeley biotech. The mission of Indee Labs is to use microfluidic vortex shedding as a scalable method to deliver CRISPR reagents into cells for developing affordable cell and gene therapies in the future. In our previous blog post, we summarized the work from their latest publication on CRISPR-editing in T cells using microfluidic devices. In ...
Recently, researchers at Notre Dame University have identified specific features of the reaction of two distinct peptide antigens to a T-cell receptor (TCR), which provides new clues to optimizing molecular structure for the development of immunotherapy of cancer cell research. ...